Compare Eaton Corporation plc (ETN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Recursion Pharmaceuticals Inc — how do they compare? Eaton Corporation plc trades at $463.03 (market cap $172.82B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Eaton Corporation plc is far larger — about 97.1× Recursion Pharmaceuticals Inc's market cap, and Eaton Corporation plc pays a 0.99% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ETN | RXRX | |
|---|---|---|
Market Cap | $172.82B | $1.78B |
Sector | Technology | Health |
52-Week High | $459.29 | $6.79 |
52-Week Low | $315.82 | $2.84 |
Enterprise Value | $193.45B | $1.30B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton (ETN) trades at $448.68, up 0.11% on the day and near its 52-week high, supported by a bullish technical trend and strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.15 exceeding the $3.07 estimate, and raised its full-year outlook. Revenue growth is robust, driven by surging demand in electrical and aerospace segments, particularly from data center expansion.
The outlook remains positive given raised guidance and analyst consensus, but the stock's premium valuation (P/E of 45.31) poses a risk if growth moderates. Key opportunities include exposure to AI-driven power infrastructure spending, while risks involve execution challenges and macroeconomic sensitivity. The consensus price target of $496.50 implies ~11% upside from current levels.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
